XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Capital Stock, Stock Plans and Stock-Based Compensation | 6 Months Ended
--- | ---
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |
Capital Stock, Stock Plans and Stock-Based Compensation |
5. | Capital Stock, Stock Plans and Stock-Based Compensation
The Company has certain stock option plans under which it awards incentive and non-qualified stock options to employees, officers, and outside directors. On January 18, 2018, the Company granted 6,000 options from the Company’s 2003 Outside Directors Stock Plan to a new director elected by the Company’s Board of Directors (“Board”) to fill a vacancy on the Board. The options granted were for a contractual term of ten years with a vesting period of six months. The exercise price of the options was $4.05 per share, which was equal to our closing stock price the day preceding the grant date, pursuant to the 2003 Outside Directors Stock Plan. On January 13, 2017, the Company granted 6,000 options from the Company’s 2003 Outside Directors Stock Plan to a new director elected by the Company’s Board to fill a vacancy on the Board. The options granted were for a contractual term of ten years with a vesting period of six months. The exercise price of the options was $3.79 per share, which was equal to our closing stock price the day preceding the grant date, pursuant to the 2003 Outside Directors Stock Plan. The Company estimates fair value of stock options using the Black-Scholes valuation model. Assumptions used to estimate the fair value of stock options granted include the exercise price of the award, the expected term, the expected volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and the expected annual dividend yield. The fair value of the options granted on January 18, 2018 and January 13, 2017 as discussed above and the related assumptions used in the Black-Scholes option model used to value the options granted were as follows:
|  | Outside Director Stock Options Granted |
|  | January 18, 2018 |  |  | January 13, 2017 |
Weighted-average fair value per option |  | $ | 2.55 |  |  | $ | 2.63 |
Risk -free interest rate (1) |  |  | 2.62 | % |  |  | 2.40 | %
Expected volatility of stock (2) |  |  | 57.29 | % |  |  | 56.32 | %
Dividend yield |  |  | None |  |  |  | None |
Expected option life (3) |  |  | 10.0 years |  |  |  | 10.0 years |
(1) | The risk-free interest rate is based on the U.S. Treasury yield in effect at the grant date over the expected term of the option.
(2) | The expected volatility is based on historical volatility from our traded Common Stock over the expected term of the option.
(3) | The expected option life is based on historical exercises and post-vesting data.
The following table summarizes stock-based compensation recognized for the three and six months ended June 30, 2018 and 2017 for our employee and director stock options.
|  | Three Months Ended |  |  | Six Months Ended |
Stock Options |  | June 30, |  |  | June 30, |
|  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
Employee Stock Options |  | $ | 37,000 |  |  | $ | 11,000 |  |  | $ | 73,000 |  |  | $ | 21,000 |
Director Stock Options |  |  | 8,000 |  |  |  | 8,000 |  |  |  | 18,000 |  |  |  | 20,000 |
Total |  | $ | 45,000 |  |  | $ | 19,000 |  |  | $ | 91,000 |  |  | $ | 41,000 |
At June 30, 2018, the Company has approximately $503,000 of total unrecognized compensation cost related to unvested options, of which $75,000 is expected to be recognized in remaining 2018, $126,000 in 2019, $114,000 in 2020, $114,000 in 2021, with the remaining $74,000 in 2022. The summary of the Company’s total Stock Option Plans as of June 30, 2018 and June 30, 2017, and changes during the periods then ended, are presented below. The Company’s Plans consist of the 2010 and 2017 Stock Option Plans and the 2003 Outside Directors Stock Plan:
|  | Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (years) |  |  | Aggregate Intrinsic Value (3) |
Options outstanding January 1, 2018 |  |  | 624,800 |  |  | $ | 4.42 |  |  |  |  |  |  |  |  |
Granted |  |  | 6,000 |  |  |  | 4.05 |  |  |  |  |  |  |  |  |
Exercised |  |  | (10,000 | ) |  |  | 3.65 |  |  |  |  |  |  |  |  |
Forfeited/expired |  |  | ─ |  |  |  | ─ |  |  |  |  |  |  |  |  |
Options outstanding end of period (1) |  |  | 620,800 |  |  | $ | 4.43 |  |  |  | 5.0 |  |  | $ | 435,870 |
Options exercisable at June 30, 2018(1) |  |  | 198,133 |  |  | $ | 6.07 |  |  |  | 4.3 |  |  | $ | 78,836 |
Options exercisable and expected to be vested at June 30, 2018 |  |  | 620,800 |  |  | $ | 4.43 |  |  |  | 5.0 |  |  | $ | 435,870 |
|  | Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (years) |  |  | Aggregate Intrinsic Value (3) |
Options outstanding January 1, 2017 |  |  | 247,200 |  |  | $ | 6.69 |  |  |  |  |  |  |  |  |
Granted |  |  | 6,000 |  |  |  | 3.79 |  |  |  |  |  |  |  |  |
Exercised |  |  | ─ |  |  |  | ─ |  |  |  |  |  |  |  |  |
Forfeited/expired |  |  | (30,000 | ) |  |  | 5.00 |  |  |  |  |  |  |  |  |
Options outstanding end of period (2) |  |  | 223,200 |  |  | $ | 6.84 |  |  |  | 4.5 |  |  | $ | 13,080 |
Options exercisable at June 30, 2017(2) |  |  | 180,534 |  |  | $ | 7.51 |  |  |  | 4.3 |  |  | $ | 13,080 |
Options exercisable and expected to be vested at June 30, 2017 |  |  | 223,200 |  |  | $ | 6.84 |  |  |  | 4.5 |  |  | $ | 13,080 |
(1) Options with exercise prices ranging from $2.79 to $13.35 (2) Options with exercise prices ranging from $2.79 to $14.75 (3) The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price of the option. During the six months ended June 30, 2018, the Company issued a total of 31,567 shares of its Common Stock under the 2003 Outside Directors Stock Plan to its outside directors as compensation for serving on our Board. The Company has recorded approximately $130,000 in compensation expenses for the six months ended June 30, 2018 (included in selling, general and administration expenses) in connection with the issuance of shares of its common stock to outside directors. On May 1, 2018, Robert Ferguson exercised an option from the Company’s 2017 Stock Option Plan for the purchase of 10,000 shares of the Company’s Common Stock at $3.65 per share, resulting in total proceeds received by the Company in the amount of $36,500. Robert Ferguson is a consultant to the Company in connection with the Company’s Test Bed Initiative (“TBI”) at its Perma-Fix Northwest Richland, Inc. facility and is also an advisor to the Company’s Board of Directors. The option exercised by Robert Ferguson was granted to him on July 27, 2017 in connection with his consulting work for the TBI.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration